XML 34 R23.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Basis of Presentation and Summary of Significant Accounting Policies (Tables) | 6 Months Ended
--- | ---
Dec. 31, 2024
Notes Tables |
Schedule of restructuring charges | The restructuring and restructuring-related charges for periods presented were recorded in the Consolidated Statements of Earnings as follows (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Quarter Ended | ​ | Six Months Ended
​ | ​ | December 31, | ​ | December 31,
​ | ​ | 2024 | ​ | 2024
Cost of sales | ​ | $ | 2,691 | ​ | $ | 7,589
Selling, general and administrative(1) | ​ | ​ | 273 | ​ | ​ | 5,644
Total | ​ | $ | 2,964 | ​ | $ | 13,233
(1) Restructuring actions impacting research and development are not material to separately disclose and have been included within Selling, general and administrative costs. Restructuring and restructuring-related costs by segment are as follows (in thousands):
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three months ended December 31, 2024
​ | ​ | ​ | Employee | ​ | ​ | Asset-related | ​ | ​ | ​
​ | ​ | ​ | severance | ​ | ​ | and other | ​ | ​ | Total
Protein Sciences | ​ | $ | 39 | ​ | $ | 2,755 | ​ | $ | 2,794
Diagnostics and Spatial Biology | ​ | ​ | (19) | ​ | ​ | — | ​ | ​ | (19)
Corporate | ​ | ​ | 185 | ​ | ​ | 4 | ​ | ​ | 189
Total | ​ | $ | 205 | ​ | $ | 2,759 | ​ | $ | 2,964
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Six months ended December 31, 2024
​ | ​ | ​ | Employee | ​ | ​ | Asset-related | ​ | ​ | ​
​ | ​ | ​ | severance | ​ | ​ | and other | ​ | ​ | Total
Protein Sciences | ​ | $ | 2,313 | ​ | $ | 10,172 | ​ | $ | 12,485
Diagnostics and Spatial Biology | ​ | ​ | 425 | ​ | ​ | — | ​ | ​ | 425
Corporate | ​ | ​ | 319 | ​ | ​ | 4 | ​ | ​ | 323
Total | ​ | $ | 3,057 | ​ | $ | 10,176 | ​ | $ | 13,233
​ ​ The following table summarizes the changes in the Company’s accrued restructuring balance, which is included within Other current liabilities in the accompanying balance sheet. Other amounts reported as restructuring and restructuring-related costs in the accompanying statements of income have been summarized in the notes to the table (in thousands):
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Employee | ​ | Asset | ​ | ​
​ |  | severance(1) |  | impairment and other(2) |  | Total
Expense incurred in the first quarter of 2025 | ​ | $ | 2,852 | ​ | $ | 7,417 | ​ | $ | 10,269
Cash payments | ​ | ​ | (189) | ​ | ​ | — | ​ | ​ | (189)
Non-cash adjustments | ​ | ​ | — | ​ | ​ | (7,417) | ​ | ​ | (7,417)
Accrued restructuring actions balance as of September 30, 2024 | ​ | $ | 2,663 | ​ | $ | — | ​ | $ | 2,663
Expense incurred in the second quarter of 2025 | ​ | ​ | 205 | ​ | ​ | 2,759 | ​ | ​ | 2,964
Cash payments | ​ | ​ | (1,211) | ​ | ​ | (335) | ​ | ​ | (1,546)
Non-cash adjustments | ​ | ​ | — | ​ | ​ | (2,424) | ​ | ​ | (2,424)
Accrued restructuring actions balance as of December 31, 2024 | ​ | $ | 1,657 | ​ | $ | — | ​ | $ | 1,657
(1) Relates to impacted employees’ final paycheck, separation payments, outplacement services, legal fees, and retention packages related to the closure or relocation of certain manufacturing sites. (2) Primarily relates to impairment of intangibles and inventory as a result of the closure and relocation of certain manufacturing sites. The restructuring and restructuring-related charges, including the impairment of assets held-for-sale, for periods presented were recorded in the Condensed Consolidated Statements of Earnings as follows (in thousands):
Protein Sciences |
Notes Tables |
Schedule of restructuring charges | Restructuring actions, including cash and non-cash impacts, were as follows (in thousands): ​
​ | ​ | ​ | ​
​ | ​ | Employee
​ | ​ | severance
Accrued restructuring actions balance as of June 30, 2023 | ​ | $ | 897
Fiscal year 2024 cash payments | ​ | ​ | (1,118)
First quarter fiscal year 2024 adjustments(1) | ​ | ​ | 89
Second quarter fiscal year 2024 adjustments(1) | ​ | ​ | 132
Accrued restructuring actions balance as of June 30, 2024 | ​ | $ | —
(1) Fiscal year 2024 adjustments relate to the refinement of the accrual recorded in fiscal year 2023.

X
- Definition Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details
Name: | us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_TableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=tech_ProteinSciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |